Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

DSpace Repository

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

Author: Gallwitz, Baptist; Guzman, Juan; Dotta, Francesco; Guerci, Bruno; Simo, Rafael; Basson, Bruce R.; Festa, Andreas; Kiljanski, Jacek; Sapin, Helene; Trautmann, Michael; Schernthaner, Guntram
Tübinger Autor(en):
Gallwitz, Baptist
Published in: Lancet (2012), Bd. 379, H. 9833, S. 2270-2278
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S0140-6736(12)60479-6
ISSN: 0140-6736
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)